内分泌代谢系统疾病与继发性骨质疏松症的研究新进展  

Progress in the Research of Endocrine and Metabolic System Diseases and Secondary Osteoporosis

作　　者：陈钡钡 李佳 谭文彬[2,3] CHEN Beibei;LI Jia;TAN Wenbin(Graduate School of Guangdong Pharmaceutical University,Guangzhou 510006,China;Department of Endocrinology,General Hospital of Southern Theater Command of the People's Liberation Army,Guangzhou 510010,China;The First School of Clinical Medicine,Southern Medical University,Guangzhou 510515,China)

机构地区：[1]广东药科大学研究生院,广东省广州市510006 [2]中国人民解放军南部战区总医院内分泌科,广东省广州市510010 [3]南方医科大学第一临床医学院,广东省广州市510515

出　　处：《中国全科医学》2025年第17期2082-2091,2112,共11页Chinese General Practice

基　　金：国家重点研发计划(2021YFC2501701);广东省中央引导地方科技发展专项基金(KTP20190249)。

摘　　要：继发性骨质疏松症(SOP)与各种内分泌代谢疾病有关。骨的生长发育离不开内分泌系统的调节,甲状腺功能亢进症、性腺功能减退症、高泌乳素血症等内分泌代谢疾病可打破骨吸收和骨形成的平衡,增加OP及骨折风险。为有效管理内分泌代谢病所致的SOP,有必要深入探讨其发病机制、诊断方法及治疗方案。本文从SOP在不同内分泌代谢疾病群体中的流行病学特征、激素失衡及细胞信号通路异常等发病机制、骨代谢指标与骨密度等骨损害特点,以及诊疗进展4个方面进行论述,为内分泌代谢系统疾病患者防治SOP提供参考。Secondary osteoporosis(OP)is mostly related to endocrine and metabolic diseases.The growth and development of bone is inseparable from the regulation of the endocrine system.Endocrine and metabolic diseases such as hyperthyroidism,hypogonadism,and hyperprolactinemia can break the balance between bone resorption and bone formation,and increase the risk of osteoporosis and fracture.In order to effectively manage secondary OP caused by endocrine and metabolic diseases,it is particularly important to explore its mechanism,diagnostic methods and treatment options.This article reviews the epidemiological characteristics of secondary osteoporosis in different groups of endocrine and metabolic diseases,the pathogenesis of hormone imbalance and cell signaling pathway abnormalities,the characteristics of bone damage such as bone metabolism indicators and bone mineral density,and the progress in the diagnosis and treatment of secondary osteoporosis,so as to provide reference for the prevention and treatment of secondary osteoporosis in patients with endocrine and metabolic diseases.

关 键 词：继发性骨质疏松症 骨质疏松 甲状腺功能亢进症 高泌乳素血症 性腺功能减退症 发病机制 治疗 

分 类 号：R681[医药卫生—骨科学]